Hepatitis E Virus Fluorescence Reduction Neutralization Test for Measuring Neutralizing Antibody Titers
May 22nd, 2026
There is no standard virus neutralization assay available for the Hepatitis E Virus (HEV), a non-cytopathic positive-strand RNA virus. Here, a fluorescence reduction neutralization test (FRNT)-based on quantification of fluorescent labeled viral capsid protein is described for evaluating the efficacy of anti-HEV antibodies.
The main purpose of fluorescence reduction-based neutralization test is to quantify the neutralization potential of a vaccine candidate and antibodies against HEV. HEV's known cytopathic nature limits PRND assay. This protocol focuses on immuno-based training PRND so to visualize infected cells and later mine-To begin, count the freshly split HuH-7 cells.
Then, place a microscopy-grade glass cover slip in a 12-well plate, and seed 0.2 million cells per well in one milliliter complete DMEM supplemented with 10%FBS. Incubate the cells overnight at 37 degrees Celsius with 5%carbon dioxide. On the next day, add 500 microliters serum-free media containing 1.8 times 10 to the power of four genome copies of purified g1-HEV to the seeded cells.
Incubate at 37 degrees Celsius with 5%carbon dioxide for one hour. Use 500 microliters DPBS to wash the cells three times. Add two milliliters of DMEM supplemented with 2%FBS to the wells.
Incubate the cells at 37 degrees Celsius with 5%carbon dioxide for 72 hours. Wash the cells three times with 500 microliters DPBS, incubating for five minutes at room temperature between each wash. Add 500 microliters 4%paraformaldehyde to the cells, and incubate them at room temperature for 20 minutes.
Then, wash the cells with DPBS as demonstrated earlier. After the final wash, incubate them in DPBS for 30 minutes at room temperature. Add 250 microliters of blocking solution containing 5%normal goat serum, 0.5%bovine serum albumin, and 0.3%Triton X100 in DPBS.
Incubate in a shaker for one hour at room temperature. Remove the blocking solution, and wash once with 500 microliters DPBS. Then add 250 microliters of primary antibody solution at a one-to-500 dilution.
Incubate the cells overnight at four degrees Celsius. The next day, wash the cells with DPBS three times as demonstrated earlier. Add 100 microliters of secondary antibody at one-to-1, 000 dilution, and incubate for one hour at room temperature in a humified chamber.
Perform the wash incubate cycle as demonstrated earlier. Add 10 microliters antifade reagent with DAPI onto a glass slide. Mount the cover slip with cells facing the reagent while avoiding air bubbles.
Seal the cover slip with nail polish to preserve it for confocal microscopy visualization. Count freshly split HuH-7 cells. Then, place a microscopy grade glass cover slip in a 12-well plate, and seed 0.2 million cells in one milliliter complete DMEM per well.
The next day, prepare a tenfold serial dilution of anti-ORF2 and rabbit immunoglobulin G antibodies in serum-free media, with a starting antibody concentration of 25 micrograms per milliliter, and up to a final dilution of 10 to the power of minus five. The final volume of the dilution should be 100 microliters. Then, add 1.8 times 10 to the power of four genome copies of purified g1-HEV to each antibody dilution.
Incubate the antibody virus mixture at 37 degrees Celsius with 5%carbon dioxide for one hour. Wash the cells with 500 microliters of DPBS. Add the antibody virus mixture to the cells.
Incubate at 37 degrees Celsius with 5%carbon dioxide for one hour. Wash the cells with 500 microliters buffer. After adding DMEM with 2%FBS, incubate for 72 hours at 37 degrees Celsius with 5%carbon dioxide.
Process the cells for immunofluorescent staining as demonstrated previously. After acquiring the fluorescence images, open the ImageJ software. Select File, and open the image.
Then, select Image, Type, and click 8-bit to convert the RGB image to 8-bit format. Adjust the threshold by selecting Image and choosing Adjust, then Threshold, setting the lower level to 40, and upper level to 255. Select Analyze, choose Analyze Particles, and enable Display results, Clear results, Summarize, Exclude on edges, and Composite regions of interest.
Then click OK to obtain fluorescent spot counts. Calculate percent neutralization and NT50 as the antilog of Log10 NT50, using the formula provided. Plot the graph showing mean and standard deviation of all fields.
A significant level of g1-HEV ribonucleic acid was detected in infected cells compared to mock-infected cells. Immunofluorescence assay using anti-ORF2 antibody confirmed ORF2 expression in the infected HuH-7 cells. The 50%neutralization titer of the anti-ORF2 antibody was estimated to be 2.1 times 10 to the power of three.
Representative images show the appearance of mock-infected and g1-HEV infected HuH-7 cells in the fluorescence reduction neutralization test. This protocol allow researchers to study the neutralization potential of anti-HEV antibodies and measure their 50%neutralization titer. The critical step of this protocol is isolation of infectious hepatitis E virus and proper cell staining and acquisition of high-resolution images.
Alternative methods such as RT-qPCR and ELISA can be used to determine neutralization titer, but they have some limitations.
View the full transcript and gain access to thousands of scientific videos
Overview
This article describes a fluorescence reduction neutralization test (FRNT) designed to measure the neutralization potential of antibodies against Hepatitis E virus (HEV). The method provides a valuable alternative to plaque reduction neutralization tests (PRNT), which are not feasible for non-cytopathic viruses like HEV. The FRNT enables researchers to estimate the 50% neutralization titre (NT50) of anti-HEV antibodies, supporting vaccine and therapeutic antibody development.
Key Study Components
Area of Science
- Virology
- Immunology
- Vaccine development
Background
- Virus neutralization assays assess the efficacy of antibodies or vaccines against specific viruses.
- PRNT is commonly used but unsuitable for non-cytopathic viruses such as HEV.
- HEV is a major cause of acute viral hepatitis and lacks widespread vaccine or therapeutic antibody availability.
- Reliable neutralization assays are needed to evaluate HEV vaccine candidates and antibody responses.
Purpose of Study
- To develop and describe a fluorescence-based neutralization assay for HEV.
- To provide a method for estimating the NT50 of anti-HEV antibodies.
- To facilitate the evaluation of vaccine candidates and antibody efficacy against HEV.
Methods Used
- HEV was neutralized with anti-HEV ORF2 antibodies or rabbit IgG.
- Neutralized virus was used to infect Huh7 cells.
- Immunofluorescent staining targeted the viral ORF2 protein.
- Fluorescent positive cells were quantified using ImageJ software.
- NT50 values were calculated based on fluorescence reduction.
Main Results
- The FRNT successfully estimated the NT50 of anti-HEV antibodies.
- The NT50 was determined to be 2.1 x 103 for the tested antibodies.
- The method is applicable to sera from immunized mice, HEV-recovered individuals, and laboratory-produced antibodies.
Conclusions
- The FRNT provides a practical and effective assay for measuring HEV-neutralizing antibodies.
- This method supports the evaluation of vaccine candidates and antibody-based therapies for HEV.
- It addresses the limitations of PRNT for non-cytopathic viruses.
Frequently Asked Questions
Executive Industry Relevance
Quantitative measurement of neutralizing antibody titers against Hepatitis E virus (HEV) is critical for vaccine candidate evaluation and therapeutic antibody development, especially given the lack of cytopathic effect in standard cell culture. The fluorescence reduction neutralization test (FRNT) enables robust assessment of antibody efficacy where traditional plaque assays are not feasible, directly impacting early discovery and translational research pipelines. This capability supports portfolio decisions by providing actionable data on immunogenicity and neutralization potential for HEV interventions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct quantification of antibody-mediated HEV neutralization for target validation.
- Supports mechanistic de-risking by confirming functional antibody-virus interactions.
- Provides predictive confidence for advancing vaccine and antibody candidates.
Screening & Assay Development
- Delivers a standardized, reproducible assay for measuring neutralizing titers in non-cytopathic virus systems.
- Facilitates quantitative comparison of candidate antibodies and sera from immunized or recovered subjects.
- Prepares validated biological systems for downstream screening and optimization workflows.
Translational & Preclinical Research
- Aligns neutralization data with translational biomarker strategies for HEV.
- Enables continuity from discovery-stage antibody screening to preclinical efficacy assessment.
- Supports risk-adjusted advancement of vaccine and therapeutic antibody programs.
Pipeline & Workflow Integration
The FRNT method integrates into the discovery-to-preclinical continuum by providing a quantitative, reproducible readout of antibody neutralization for HEV, bridging early candidate selection and translational validation.
- Discovery Biology: Supports hypothesis testing and biological de-risking by quantifying neutralization capacity.
- Screening: Offers assay readiness and reproducibility for evaluating multiple antibody or serum samples.
- Analytics: Provides quantitative NT50 measurements to compare neutralizing potency across conditions.
- Translational Research: Links in vitro neutralization to preclinical biomarker strategies for HEV.
- Enterprise Reuse: Establishes a reusable platform for neutralization testing in non-cytopathic virus research.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in HEV antibody evaluation.
- Operational Value: Standardizes neutralization testing for non-cytopathic viruses, improving reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient advancement of HEV vaccine and antibody assets.
- Portfolio Impact: Supports risk-adjusted prioritization of candidates based on quantitative neutralization data.
Implementation Considerations
- Requires expertise in immunofluorescence and quantitative image analysis.
- Needs access to Huh7 cell culture, immunostaining reagents, and fluorescence microscopy.
- Demands cross-team standardization for assay setup and data interpretation.
- Adaptation to other non-cytopathic viruses may require protocol optimization.
- Dependent on availability of validated anti-HEV antibodies and reference sera.